The Algerian Ministry of Pharmaceutical Industry recently met with representatives from the US-based laboratory Abbott and the Algerian-American Business Council to discuss a potential partnership to manufacture modern blood glucose monitoring devices in Algeria. The meeting, which took place in Algiers, was attended by Abdelhakim Boudis, the head of the ministry's secretariat, and Samy Boukaila, president of the Algerian-American Business Council. The proposed project aims to introduce a modern technology that enables continuous and precise monitoring of blood glucose levels.
The devices are particularly crucial for children with diabetes, and the partnership would facilitate their daily monitoring and improve the quality of healthcare they receive. During the meeting, Boudis emphasized the importance of establishing a partnership that goes beyond commercializing the technology in the local market. He stressed the need for technology transfer, knowledge sharing, and exchange of expertise, as well as localizing production to ensure a sustainable supply of the devices.
The Algerian government is keen on promoting local production and developing national competencies in the medical technology sector. The ministry's orientations focus on strengthening partnerships in research and development, specialized training, and technology transfer. By partnering with Abbott, Algeria aims to enhance its capabilities in producing high-quality medical devices and improve healthcare outcomes for patients with diabetes.
The meeting also discussed the possibility of manufacturing the devices locally to guarantee their availability and accessibility to patients. This move would reinforce national capacities in medical technology and contribute to the country's goal of becoming self-sufficient in producing essential medical supplies. The partnership would also create opportunities for knowledge sharing and skills development in the local workforce.
The Algerian-American Business Council and Abbott representatives expressed their interest in collaborating with the Algerian government to make the project a reality. The two parties acknowledged the potential benefits of the partnership, including improved healthcare outcomes, job creation, and technology transfer. They agreed to continue discussions to finalize the details of the partnership.
The project aligns with Algeria's efforts to develop its pharmaceutical industry and improve healthcare services. The country has been investing in its healthcare sector, with a focus on enhancing medical infrastructure, training healthcare professionals, and promoting local production of medical supplies. The partnership with Abbott would be a significant step towards achieving these goals.
The proposed partnership between Algeria and Abbott has the potential to make a positive impact on the lives of patients with diabetes in Algeria. With a reliable supply of blood glucose monitoring devices, patients would be able to manage their condition more effectively, and healthcare providers would be able to offer better care. The project is expected to contribute to the country's healthcare development and improve the overall quality of life for patients with diabetes.
Key points
- Algeria is exploring a partnership with US-based Abbott to manufacture blood glucose monitoring devices locally.
